Shopping Cart

Your shopping cart is currently empty

Gartisertib

Name: Gartisertib
Brand: TargetMol
SKU: T10407
Price: 129 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T10407Cas No. 1613191-99-3

Alias VX-803, VX 03, VRT1228692, M4344, M 4344, ATR inhibitor 2

Gartisertib (VX-803) is an orally active and selective Rad3-related protein (ATR) inhibitor with antitumor activity, inhibiting the antiproliferative effect induced in ccRCC cells, and inhibiting ATR-driven phosphorylation of checkpoint kinase 1 (Chk1), useful for studying solid tumors.

Gartisertib

Copy Product Info

😃Good

Purity: 99.52%

Catalog No. T10407Alias VX-803, VX 03, VRT1228692, M4344, M 4344, ATR inhibitor 2Cas No. 1613191-99-3

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$129	-	In Stock
5 mg	$322	-	In Stock
10 mg	$538	-	In Stock
25 mg	$1,070	-	In Stock
50 mg	$1,570	-	In Stock
100 mg	$2,360	-	In Stock
1 mL x 10 mM (in DMSO)	$383	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.52%

Appearance:Solid

Color:Yellow

Resource Download

COA HPLC HNMR FNMR

Product Introduction

Bioactivity

Description	Gartisertib (VX-803) is an orally active and selective Rad3-related protein (ATR) inhibitor with antitumor activity, inhibiting the antiproliferative effect induced in ccRCC cells, and inhibiting ATR-driven phosphorylation of checkpoint kinase 1 (Chk1), useful for studying solid tumors.
Targets&IC50	ATR:8 nM
In vitro	Gartisertib was four times more potent in all glioblastoma cell lines than the widely used ATR inhibitor berzosertib (Gartisertib median IC50 = 0.56 μM, berzosertib median IC50 = 2.21 μM). In addition, Gartisertib observed a higher IC50 (7.22 μM) in human astrocytes, indicating a lower potential toxicity of Gartisertib to normal brain cells. The combination of Gartisertib (1 μM) with TMZ+RT significantly increased apoptosis and cell death in patient-derived glioblastoma cell lines. [1]
In vivo	Gartisertib (10 mg/kg or 20 mg/kg) plus cisplatin inhibited tumor growth in metastatic clear cell renal cell carcinoma (ccRCC) xenografts, demonstrating therapeutic synergies. [2]
Synonyms	VX-803, VX 03, VRT1228692, M4344, M 4344, ATR inhibitor 2

Chemical Properties

Molecular Weight	541.55
Formula	C₂₅H₂₉F₂N₉O₃
Cas No.	1613191-99-3
Smiles	O=C(NC=1C=NC=C(F)C1N2CCC(C(=O)N3CCN(CC3)C4COC4)CC2)C=5C(=NN6C=C(F)C=NC56)N
Relative Density.	1.31g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 16 mg/mL (29.54 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Saline: 1.5 mg/mL (2.77 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.8466 mL	9.2328 mL	18.4655 mL	92.3276 mL
5 mM	0.3693 mL	1.8466 mL	3.6931 mL	18.4655 mL
10 mM	0.1847 mL	0.9233 mL	1.8466 mL	9.2328 mL
20 mM	0.0923 mL	0.4616 mL	0.9233 mL	4.6164 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc